Surmodics (SRDX) Projected to Post Quarterly Earnings on Wednesday

Surmodics (NASDAQ:SRDX) is expected to be releasing its Q4 2025 results before the market opens on Wednesday, November 5th. Analysts expect Surmodics to post earnings of ($0.19) per share and revenue of $30.14 million for the quarter. Surmodics has set its FY 2025 guidance at -0.350–0.200 EPS.Interested persons are encouraged to explore the company’s upcoming Q4 2025 earningoverview page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 12:30 PM ET.

Surmodics (NASDAQ:SRDX) last posted its earnings results on Friday, August 8th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of ($0.21) by $0.27. Surmodics had a negative return on equity of 2.99% and a negative net margin of 14.59%.The firm had revenue of $29.57 million for the quarter, compared to analysts’ expectations of $28.04 million. On average, analysts expect Surmodics to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Surmodics Stock Down 0.4%

SRDX opened at $27.36 on Wednesday. Surmodics has a 12 month low of $26.00 and a 12 month high of $40.38. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.91 and a quick ratio of 3.10. The stock has a market cap of $391.25 million, a P/E ratio of -22.24 and a beta of 1.31. The stock’s 50 day moving average price is $31.08 and its 200 day moving average price is $30.81.

Analysts Set New Price Targets

SRDX has been the topic of several research analyst reports. Barrington Research reiterated a “market perform” rating on shares of Surmodics in a research report on Monday, August 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Surmodics in a research report on Wednesday, October 8th. Finally, Zacks Research upgraded Surmodics to a “hold” rating in a research report on Tuesday, August 12th. One analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Surmodics presently has a consensus rating of “Hold” and an average target price of $43.00.

Hedge Funds Weigh In On Surmodics

Hedge funds have recently modified their holdings of the stock. Russell Investments Group Ltd. grew its holdings in shares of Surmodics by 705.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock worth $37,000 after acquiring an additional 1,080 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in shares of Surmodics by 67.6% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,435 shares of the company’s stock worth $43,000 after acquiring an additional 579 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Surmodics by 289.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,730 shares of the company’s stock worth $51,000 after acquiring an additional 1,286 shares during the last quarter. Strs Ohio acquired a new position in shares of Surmodics in the 1st quarter worth $122,000. Finally, Creative Planning acquired a new position in shares of Surmodics in the 2nd quarter worth $318,000. 96.63% of the stock is currently owned by institutional investors and hedge funds.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).